-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Neutral on Halozyme Therapeutics, Raises Price Target to $81

Benzinga·11/20/2026 17:35:46
Listen to the news
JP Morgan analyst Jessica Fye maintains Halozyme Therapeutics (NASDAQ:HALO) with a Neutral and raises the price target from $79 to $81.